Acorda Therapeutics Acquisitions and Exits, 4 Deals Between 2012 and 2018
life science Company

Acorda Therapeutics has acquired 3 companies, including 2 in the last 5 years. A total of 1 acquisition came from private equity firms. It has also divested 1 asset.

Acorda Therapeutics’ largest acquisition to date was in 2014, when it acquired Civitas Therapeutics for $525M. Acorda Therapeutics has acquired in 2 different US states, and 2 countries. The Company’s most targeted sectors include life science (100%).

Join Mergr and gain access to Acorda Therapeutics’ M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.

Acorda Therapeutics, Inc.

420 Saw Mill River Road,
Ardsley, New York 10502
United States,
(914) 347-4300
www.acorda.com

Acorda Therapeutics, Inc. is a biotechnology company developing therapies for multiple sclerosis and related neurological conditions such as spinal cord injury (SCI). Acorda Therapeutics, Inc. was formed in 1995 and is headquartered in Ardsley, New York.

M&A Summary

Buy vs Sell

Year ≤ '14 '15 '16 '17 '18 '19 T
Buy (0.2/yr) # 2 - 1 - - - 3
vol $625M $363M $988M
Sell (0.2/yr) # - - - - 1 - 1
  4

Top M&A Advisors

Financial Deals
Sign-up to View
2
Sign-up to View
2
Sign-up to View
1
Legal Deals
Sign-up to View
1
Sign-up to View
1
Sign-up to View
1

Deal Values

Buy # TOTAL
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
TOTAL Sign-up to View
Largest Civitas Therapeutics, Inc.
$525M (2014-09-24)
Sell # Total
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
Total Sign-up to View

Life Science M&A - Last 3 Years

When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 403 life science companies that have made at least 1 acquisition, 13 have acquired at least 5 companies, and 2 have acquired more than 10 companies.

The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 25 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is The Carlyle Group with 5 platform acquisitions.


What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.5K Private Equity Firms
  • 125K M&A Transactions
  • 134K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.9K M&A Advisors
    (Investment Banks and Law Firms)
  • 35K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.